Hiro Nitta

Title: Hiro Nitta: Innovator in Lung Cancer Treatment

Introduction

Hiro Nitta is a prominent inventor based in Tucson, Arizona, known for his significant contributions to the field of oncology. With a total of five patents to his name, Nitta has focused on developing methods that enhance the treatment of non-small cell lung cancer (NSCLC). His innovative approaches have the potential to improve patient outcomes and advance cancer treatment methodologies.

Latest Patents

One of Nitta's latest patents involves a method of identifying treatment-responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker. This patent discloses methods for identifying a subject as having NSCLC that is predicted or likely to respond to treatment with an ALK inhibitor, such as crizotinib. The methods include identifying a sample containing NSCLC tumor cells as ALK-positive or ALK-negative through immunohistochemistry (IHC) and scoring methods. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive. Conversely, if the sample is identified as ALK-negative, the subject is considered not likely to respond to treatment with an ALK inhibitor. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with such an inhibitor.

Career Highlights

Throughout his career, Hiro Nitta has worked with notable organizations, including Ventana Medical Systems, Inc. and Nihon University School of Medicine. His work in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in cancer treatment.

Collaborations

Nitta has collaborated with esteemed colleagues, including Michael S. Barnes and June F. Clements. These partnerships have fostered an environment of innovation and have led to advancements in the understanding and treatment of lung cancer.

Conclusion

Hiro Nitta's contributions to the field of oncology, particularly in the treatment of non-small cell lung cancer, highlight his role as an influential inventor. His innovative methods and collaborations continue to pave the way for improved cancer therapies and patient care.